Bibliographie (2362)
Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.
dimanche, 09 janvier 2022 03:03 Écrit par Zouhair SouissiRisk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data – Annals of Internal Medicine Commentaries: Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology
The post Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban. appeared first on Links Medicus.
Diagnostics for COVID-19: moving from pandemic response to control.
dimanche, 09 janvier 2022 03:03 Écrit par Zouhair SouissiDiagnostics for COVID-19: moving from pandemic response to control – The Lancet Commentary on Twitter Diagnostics—crucial during the #COVID19 pandemic. A new Review discusses the 3 major methods for detection of SARS-CoV-2 infection & their evolution over time: moving from pandemic response to control. Learn more ? https://t.co/6Him1H3VG7 pic.twitter.com/jt7yHkolCK — The Lancet (@TheLancet) December […]
The post Diagnostics for COVID-19: moving from pandemic response to control. appeared first on Links Medicus.
New CDC Guidance shortens isolation and quarantine period for Covid-19; patients that tested positive should isolate for 5 days and, if asymptomatic after this period, can leave isolation if they can continue to mask for 5 days to minimize the risk of inf
dimanche, 09 janvier 2022 03:03 Écrit par Zouhair SouissiCDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population – Centers for Disease Control and Prevention See also: Quarantine and Isolation – Centers for Disease Control and Prevention Commentaries: Facing criticism, CDC updates Covid-19 isolation recommendations with guidance on testing – CNN CDC posts rationale for shorter isolation, quarantine – Associated Press […]
The post New CDC Guidance shortens isolation and quarantine period for Covid-19; patients that tested positive should isolate for 5 days and, if asymptomatic after this period, can leave isolation if they can continue to mask for 5 days to minimize the risk of infecting others. appeared first on Links Medicus.
Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests.
vendredi, 17 décembre 2021 11:11 Écrit par Zouhair SouissiNews Release: Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests – Oregon Health & Science University Original Study: Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection – JAMA
The post Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests. appeared first on Links Medicus.
RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.
vendredi, 17 décembre 2021 11:11 Écrit par Zouhair SouissiRivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet Invited commentary: Anticoagulation in COVID-19 – The Lancet Commentary on Twitter NEW: The role of extended thromboprophylaxis in patients hospitalised with COVID-19 at risk for thrombotic events after discharge – findings from MICHELLE […]
The post RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes. appeared first on Links Medicus.
Covid-19: Runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show.
vendredi, 17 décembre 2021 11:11 Écrit par Zouhair SouissiCovid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show – The BMJ See also: Omicron and cold-like symptoms rapidly taking over in London – ZOE COVID Study Commentary on Twitter The UK government has been urged to update its list of symptoms for covid-19, after early data showed cold-like […]
The post Covid-19: Runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show. appeared first on Links Medicus.
WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.
vendredi, 17 décembre 2021 11:11 Écrit par Zouhair SouissiInterim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post
The post WHO issues interim recommendations for heterologous COVID-19 vaccine schedules. appeared first on Links Medicus.
Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.
vendredi, 17 décembre 2021 11:11 Écrit par Zouhair SouissiEfficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – New England Journal of Medicine Commentaries: Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine Related: [Preprint] In RCT with 29,949 participants, the Novavax […]
The post Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections. appeared first on Links Medicus.
RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.
vendredi, 17 décembre 2021 11:11 Écrit par Zouhair SouissiMolnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine Related: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)
The post RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19. appeared first on Links Medicus.
Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.
jeudi, 16 décembre 2021 12:08 Écrit par Zouhair SouissiMerck’s COVID pill loses its lustre: what that means for the pandemic – Nature Related: FDA panel narrowly recommends authorization of first antiviral pill to treat COVID. [Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute […]
The post Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”. appeared first on Links Medicus.
![[Not published yet] Initial data from South Africa showed vaccine protection vs. Omicron infection may drop to 30% but does cut severe disease.](/media/k2/items/cache/084e87a704762fed2247732a795060ad_XS.jpg)
![[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.](/media/k2/items/cache/4499a0e577c756b59dbc3fc7824f3bb4_XS.jpg)